DEBIO 0513

Drug Profile

DEBIO 0513

Alternative Names: PTR-262; PTR-262-MG

Latest Information Update: 12 Aug 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DeveloGen
  • Class
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis

Highest Development Phases

  • No development reported Myasthenia gravis

Most Recent Events

  • 25 Sep 2006 DEBIO 0513 has received Orphan Drug Status in Europe for the treatment of Myasthenia gravis
  • 18 Aug 2005 DEBIO 0513 has been licensed to Debiopharm worldwide for the treatment of Myasthenia gravis
  • 14 Jun 2004 Peptor has been acquired by, and merged into, DeveloGen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top